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Retroviral integration requires cis-acting sequences at the termini of linear double-stranded viral DNA and
a product of the retroviral pol gene, the integrase protein (IN). IN is required and sufficient for generation of
recessed 3' termini of the viral DNA (the first step in proviral integration) and for integration of the recessed
DNA species in vitro. Human immunodeficiency virus type 1 (HIV-1) IN, expressed in Escherichia coli, was
purified to near homogeneity. The substrate sequence requirements for specific cleavage and integration of
retroviral DNA were studied in a physical assay, using purified IN and short duplex oligonucleotides that
correspond to the termini ofHIV DNA. A few point mutations around the IN cleavage site substantially reduced
cleavage; most other mutations did not have a drastic effect, suggesting that the sequence requirements are
limited. The terminal 15 bp of the retroviral DNA were demonstrated to be sufficient for recognition by IN.
Efficient specific cutting of the retroviral DNA by IN required that the cleavage site, the phosphodiester bond
at the 3' side of a conserved CA-3' dinucleotide, be located two nucleotides away from the end of the viral DNA,
however, low-efficiency cutting was observed when the cleavage site was located one, three, four, or five
nucleotides away from the terminus of the double-stranded viral DNA. Increased cleavage by IN was detected
when the nucleotides 3' of the CA-3' dinucleotide were present as single-stranded DNA. IN was found to have
a strong preference for promoting integration into double-stranded rather than single-stranded DNA.
Efficient retroviral replication requires integration of a
double-stranded DNA copy of the viral RNA genome into a
chromosome of the infected cell. Transcription of the inte-
grated provirus produces viral RNAs that function as ge-
nomes of progeny virions or as the template for translation of
viral proteins. Assembled virions bud from the cell mem-
brane, and infection of other cells completes the retroviral
replication cycle.
Studies of integration in the Moloney murine leukemia
virus (MoMLV), human immunodeficiency virus (HIV), and
avian sarcoma-leukosis virus (ASLV) systems have indi-
cated that the following steps are involved in the integration
process. After reverse transcription and second-strand DNA
synthesis, a linear, double-stranded DNA molecule with
flush ends is formed. This DNA copy of the viral RNA
contains at its termini direct repeat sequences, termed long
terminal repeats (LTRs). At the outer edges of the LTRs,
short, imperfect inverted repeats are present. These se-
quences are necessary and sufficient for correct proviral
integration (6, 7). The two terminal nucleotides at the 3' ends
of the blunt-ended DNA are cleaved off, resulting in the
putative immediate precursor for integration (2, 15, 26). This
cleavage reaction is executed by the viral integrase protein
(IN), which is the only protein known to be required for
integration (3, 5, 8, 18, 19, 30). In the next step, the target
DNA is cut in a staggered fashion and joined to the viral 3'
OH ends (3, 8, 15, 18). The length of the staggered cut is
virus specific (35). In the case of HIV integration, presum-
ably a 5-bp staggered cut is generated, which is inferred from
the characteristic 5-bp direct repeats in the target DNA that
flank integrated HIV proviruses (10, 21, 36). The last step in
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proviral integration is repair of the single-stranded DNA
gaps present in the integration intermediate. It is possibly in
this step that the terminal nucleotides at the proviral 5' ends
are lost. The resulting provirus is now flanked by a short
direct duplication of the target DNA and terminates with the
dinucleotides 5'-TG and CA-3'. These same dinucleotides
are also present at the termini of some eukaryotic and
prokaryotic transposable elements and in all retrotrans-
posons.
The HIV-1 IN protein is encoded near the 3' end of the
viral pol gene and is a 32-kDa proteolytic cleavage product of
a gag-pol fusion protein precursor. Mutations in the IN-
coding region have no influence on reverse transcription, but
integration of the viral DNA can be blocked (9, 28, 34). An
understanding of the role of the IN protein in the integration
process has come from the development of different in vitro
integration assays. First it was shown that extracts from
retrovirus-infected cells were able to integrate endogenous
DNA as well as exogenously added retroviral DNA (2, 10,
11, 14, 37). Thereafter it was demonstrated by a direct
physical assay that the IN proteins of HIV, MoMLV, and
ASLV are the only viral proteins that are required both to
generate the recessed 3' ends of the viral DNA and to
accomplish their integration in vitro (4, 8, 18, 30). In this
assay, oligonucleotides that represent the termini of the
retroviral DNA were incubated with IN, and it was shown
that besides specific cutting of the oligonucleotides, IN is
also capable of integrating one oligonucleotide into another.
The IN protein of HIV-1 has been overexpressed in insect
cells (5). This protein was partially purified, and it was
shown that it is able to promote integration of mini-HIV
DNA in a genetic assay. HIV-1 IN was also overproduced in
and partially purified from Escherichia coli (4, 30). For this
protein, it was demonstrated in a physical assay that it is
4636
HIV-1 INTEGRASE SUBSTRATE REQUIREMENTS 4637
capable of generating the 3' recessed ends of the retroviral
DNA. In this case, double-stranded, blunt-ended oligonucle-
otides that represent the termini of the LTRs of HIV-1 DNA
were used as substrate viral DNAs.
We overproduced HIV-1 IN in E. coli and purified it to
near homogeneity. We show here that IN has specific
integration activity as well as specific cleavage activity. The
sequence requirements for efficient specific cleavage and
integration of HIV DNA were investigated by using a series
of oligonucleotides that contain mutations relative to an
oligonucleotide that mimics the ends of HIV DNA. We
demonstrate that for specific cutting by IN, the cleavage site
(the phosphodiester bond at the 3' side of the conserved
CA-3' dinucleotide) must be located at a subterminal posi-
tion in the viral DNA. We further investigated whether IN
could carry out integration into single-stranded as well as
double-stranded DNA.
MATERIALS AND METHODS
Construction of a plasmid expressing HIV-1 IN. The HIV-1
IN expression plasmid that we constructed is essentially the
same as the plasmid described by Sherman and Fyfe (30).
The HIV-1 IN-coding sequence was derived from plasmid
pHXB-2D (13). The IN gene was subcloned into plasmid
PiAN7 (29) to generate plasmid pRP177. The sequence
5'-ATAGAT-3' at positions 3822 to 3827 in the IN-coding
sequence (24) was changed by oligonucleotide-directed mu-
tagenesis to the sequence 5'-ATCGAT-3', which is a ClaI
restriction site. In plasmid pRP177, the StuI site that is
located at position 4985 (24) was lost by fusion to the HincII
site of vector PiAN7. The adjacent BamHI site in the
polylinker of PiAN7 and the ClaI site in the IN-coding region
were used to clone the IN gene into the NdeI and BamHI
sites of the expression vector pET-3c (25), together with the
synthetic oligonucleotide 5'-TATGTTTCTAGATGGAAT-3'
and its complement, having NdeI and ClaI cohesive ends.
The ATG in the oligonucleotide (in bold print) is the trans-
lation start codon and precedes the TTT codon, which
encodes the actual IN N-terminal amino acid, phenylalanine.
In the resulting HIV-1 IN expression vector, pRP274, the IN
gene is under the control of a bacteriophage T7 RNA
polymerase promoter. E. coli BL21(DE3) was transformed
with the IN expression plasmid. In this strain, a copy of the
T7 RNA polymerase gene is present in the chromosome and
is under the control of the lacUV5 promoter.
Purification of HIV-1 IN. IN was purified as described by
Sherman and Fyfe (30), with some modifications in the
method of growing and lysis of the bacteria. Bacteria har-
boring plasmid pRP274 were grown for 16 h at 37°C in LB
broth supplemented with 50 ,ug of ampicillin per ml. The
culture was diluted 50 times in 1 liter of TB medium (27)
containing 10 mM MgSO4 and 50 ,ug of ampicillin per ml.
After 4 h of growth at 37°C, isopropyl P-D-thiogalactopyran-
oside was added to a final concentration of 0.3 mM. Three
hours after induction, cells were harvested by centrifugation
and resuspended in cold 50 mM Tris-HCI (pH 7.5)-S5 mM
dithiothreitol-1 mM EDTA-1 mg of lysozyme per ml. After
incubation on ice for 15 min, the suspension was sonicated.
The sonic extract was centrifuged for 1 h at 12,000 x g. We
found that with these modifications, we obtained virtually
pure, soluble IN (see Results).
SDS-polyacrylamide gel electrophoresis. Proteins were sep-
arated on 10% sodium dodecyl sulfate (SDS)-polyacrylamide
gels (20). Gels were silver stained by using a silver stain kit
(Sigma Chemical Co.).
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FIG. 1. HIV-1 IN expressed in and purified from E. coli. Purified
IN was subjected to SDS-polyacrylamide gel electrophoresis and
silver stained (lane 2). Lane 1, molecular size markers.
Oligonucleotide substrates. The synthetic oligonucleotides
that were tested for specific cleavage and integration by IN
are depicted in Fig. 2 to 4. Before labeling and annealing, the
oligonucleotides were purified by electrophoresis in a dena-
turing 12% polyacrylamide (20:1 acrylamide/bisacrylamide)
gel. Ten picomoles of the oligonucleotide strand to be
labeled with 32P at its 5' end was incubated with 40 ,uCi of
[.y-32P]ATP (3,000 Ci/mmol; Amersham Corp.) and 0.1 U of
T4 polynucleotide kinase (Boehringer Mannheim) in a reac-
tion volume of 10 ,ul. After incubation for 1 h at 37°C, 10 pLI
of formamide loading dye (95% formamide, 20 mM EDTA,
0.05% bromophenol blue, 0.05% xylene cyanol) was added.
The sample was incubated at 80°C for 3 min and loaded onto
a 12% denaturing polyacrylamide gel. After electrophoresis,
an X-ray film (X-Omat AR; Eastman Kodak Co.) was
exposed to the gel to localize the labeled oligonucleotide.
The oligonucleotide was then cut from the gel and eluted for
16 h at 37°C in elution buffer (27). After precipitation with
ethanol, the oligonucleotide was resuspended in H20 to an
end concentration of 0.2 pmol/I,l. Then 1 [lI (10 pmol) of the
unlabeled complementary strand was added to 10 RI of this
oligonucleotide sample, and the mixture was heated to 900C.
The DNA was annealed by slow cooling to room tempera-
ture.
Cleavage and integration reactions. Reaction conditions for
specific cleavage and integration of the oligonucleotide sub-
strates were generally as described by Craigie et al. for the
MoMLV IN protein (8). Reaction mixtures (10 ,ul) contained
75 mM NaCl, 20 mM morpholinepropanesulfonic acid
(MOPS; pH 7.2), 3 mM MnCl2, 10 mM dithiothreitol, 20%
(vol/vol) glycerol, 100 ,ug of bovine serum albumin per ml,
0.2 pmol of duplex oligonucleotide, and about 50 ng of HIV
IN protein. The reaction mixtures were at 300C for 1 h, and
the reactions were stopped by addition of 10 ,ul of formamide
loading dye. After heating to 80°C for 3 min, 5 pul of the
samples was loaded onto a 12% polyacrylamide-8 M
urea-1 x TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA)
gel and electrophoresed. The gel was fixed by incubation in
10% methanol-10% acetic acid for 30 min and dried on
Whatman 3MM paper. Reaction products were visualized by
autoradiography.
RESULTS
Purification of HIV-1 IN. The IN protein of HIV-1 was
purified to near homogeneity essentially as described by
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A 25 20 15 10 5 1
HlV-1 US 5t-TTAGTCAGTGTGGAAAATCTCTAGCAGT -3
EIIV-1 U3 TCGTTGGGAGTGAATTACCCCTTCCAGT
H TV-2 U5 AAACCGAGGCAGGAAAA'TCCCTAGCAGG
l IV- 2 U3 TCTTTCACTGTAAAACATCCCTTCCAGT
MoMI V U5 GACTACCCGTCAGCGGGGGTrCTTT1rCATT
HIV-1 U5 5t-TTAGTCAGTGTGGAAAATCTCTAGCAGT -3
mutants
(1--)>T-- ----- --------------T-
CA(2-1)>TG ------------------------TG--
A(1)>T ----------------- T--
A)1)>G --- G--
C(2)>T ------------------------T---
C(2)>G ------------------------(-;---
ACG(4-3)>GA -------- - .- - - GA----
T(5)>A ---------------------A------
C(6)>T --------------- T-------
C(8)>G -----G---------
A(10)>G ------ G-----------
AAATC(12-8)>GGGGG --- ----GGGGG---------
A(13)>C -- ---c--------------
T<->G,A<->C(26-14) G,CTGACTGTGTT---------------
MoMLV U15
mutants
T(j3) > G
IT( 4-3) >AG
GGGGG( 12-8) >AAA
C 13)>A
5 '- GACTACCCGTCAGCGGGGGTlCIr'I'lCAEI-1
-_____AG----
XTC --------- AAATC--------
-A--------------
FIG. 2. Specific cleavage and integration of oligonucleotide sub-
strates by HIV-1 IN. (A) Sequences of the 28-bp oligonucleotides
sp.cl. it. used and summary of results from the cleavage and integration
assay. The HIV-1 sequences are from reference 38, the HIV-2
++ ++ sequences are from reference 16, and the MoMLV sequences are
+ t 4 from reference 31. Numbers in parentheses refer to positions of the
nucleotides shown at the top. Only one strand of the double-
stranded substrates is shown. The 3' end of each strand represents
- - the terminus of the viral DNA. The conserved dinucleotide CA-3' is
indicated in bold print. sp.cl., specific cleavage at the phosphodi-
ester bond 3' of the CA-3' dinucleotide. Specific cleavage was
sp.cl.
+
llt. scored when the band at the position on the gel' of the specific
product was the predominant product. Int., integration. + +, high
4 level of specific cleavage or integration; +, moderate level of
t + specific cleavage or integration; +/-, low level of specific cleavage
+t - or integration; -, no specific cleavage or integration. (B) Specific
4+4 t cleavage and integration of the various substrates. The oligonucle-
++ + otides were incubated in the presence (right lane) or absence (left
++ + lane) of HIV-1 IN. The top panels show a longer exposure of the
+ +/- region of the gel containing products longer than 28 nucleotides, to
+ +
+ identify integration products. Lengths of the oligonucleotide strands
are shown on the right. Lanes contain the following substrates: 1,
HIV-1 U5; 2, HIV-1 U3; 3, HIV-2 U5; 4, HIV-2 U3; 5, MoMLV U5;
--- 6, AAATC(12-8)>GGGGG; 7, MoMLV T(3)>G; 8, C(8)>G; 9,
+ - - A(13)>C; 10, MoMLV GGGGG(12-8)>AAATC; 11, MoMLV TT(4-
+S_ _ 3)>AG; 12, A(1)>G; 13, C(2)>T; 14, A(10)>G; 15, G(-1)>T; 16,
AG(4-3)>GA; 17, CA(2-1)>TG; 18, C(2)>G; 19, A(1)>T; 20, Mo-
MLV C(13)>A; 21, C(6)>T; 22, T(5)>A; 23, T+-G,A+C(26-14).
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Sherman and Fyfe (30). Purified IN is shown on a silver-
stained SDS-polyacrylamide gel in Fig. 1. Only a few other
minor bands can be detected in the IN preparation. The
identity of the 32-kDa IN band was determined by immuno-
blotting, using polyclonal antisera that were raised against an
oligopeptide that is identical to the C-terminal 11 amino acids
of HIV-1 IN (data not shown). We found that by using some
modifications in the method of induction and lysis of the
bacteria that express IN (see Materials and Methods), we
obtained protein preparations that had a higher purity than
-28 those previously described (30).
-26 Sequence requirements for specific cleavage and integra-
tion. The sequence requirements for specific cleavage and
integration of retroviral DNA by HIV-1 IN were determined
in a physical assay. Initially, the activities of HIV-1 IN were
tested on synthetic oligonucleotides that mimic the terminal
28 bp of HIV-1, HIV-2, and MoMLV DNA. The sequences
of these oligonucleotide substrates are shown in Fig. 2A.
Purified IN was incubated with the blunt-ended oligonucle-
otides under the appropriate reaction conditions (see Mate-
rials and Methods), and the products were electrophoresed
in a denaturing polyacrylamide gel. Reaction products were
visualized by autoradiography (Fig. 2B). As was shown
previously (4, 30), HIV-1 IN is capable of specifically
removing two nucleotides from the 3' ends of the HIV-1 U3
and U5 termini. After incubation with IN, a major product of
26 nucleotides could be seen, in addition to the band
corresponding to the substrate. A minor but clear product of
24 nucleotides could also be detected, indicating that HIV-1
IN is also able to cleave, with a low efficiency, the phos-
phodiester bond between the G nucleotide at position 3 and
-28 the C nucleotide at position 2 of the U5 sequence and
-26 between the two C nucleotides at positions 2 and 3 in the U3
sequence of HIV-1 (Fig. 2A). The relevance of cleavage at
these positions is unknown. The higher reactivity of HIV-1
U5 ends than of HIV-1 U3 ends, which has previously been
described (4), was not seen; the HIV-1 U3 and U5 oligonu-
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cleotides were cleaved at approximately equal levels (Fig.
2B, lanes 1 and 2). Oligonucleotides that represent the U3
and U5 ends of HIV-2 were also good substrates for specific
cleavage by HIV-1 IN; a major product with a length of 26
nucleotides could be detected in both instances. Reaction
products that are longer than 28 nucleotides could be de-
tected after incubation of IN with both the HIV-1 and HIV-2
substrates (Fig. 2B, upper panel). It was shown for MoMLV
IN (8), ASLV IN (18), and HIV-1 IN (4) that these bands
represent products of integration of one oligonucleotide into
another. Products that are shorter than 26 nucleotides can
also be explained by integration, because the 3' ends of the
cut made in the (5') labeled strand of the target DNA remain
unjoined in the integration product. Specific cleavage and
integration were not observed when the oligonucleotides
were incubated with an extract from E. coli BL21(DE3)
transformed with plasmid pET-3c (data not shown). This
extract was subjected to the same purification procedure as
was the HIV-1 IN preparation.
HIV-1 IN is not able to cleave the MoMLV U5 oligonu-
cleotide with high specificity (Fig. 2). A nonspecific degra-
dation ladder could be observed when the MoMLV substrate
was incubated with IN.
We set out to determine the nucleotides present at the
LTR ends of HIV-1 that are required for specific cleavage
and integration by IN. For this purpose, we tested oligonu-
cleotides that contain mutations relative to the oligonucleo-
tide that represents the terminal 28 bp of the HIV-1 U5
sequence. The sequences of the different mutant substrates
are shown in Fig. 2A. The results obtained from the cleavage
and integration assay are depicted in Fig. 2B and summa-
rized in Fig. 2A. Mutations that are located in the vicinity
and at the 5' side of the IN cleavage site (the phosphodiester
bond at the 3' side of the CA-3' dinucleotide at positions 1
and 2 in Fig. 2A) all had a reducing effect on specific
cleavage and integration. The most drastic effect was seen
with the oligonucleotide that contains the CA(2-1)>TG
mutation. This substrate was not cleaved at all by IN. When
the A nucleotide at position 1 and the C nucleotide at
position 2 were mutated separately, a reduced but still
visible level of specific cutting was observed. Apparently,
both positions are important, and the added effect of the
double mutant [CA(2-1)>TG] is a total block of cleavage.
Although integrations of mutants C(2)>G and C(2)>T were
observed, no integrations were seen of the oligonucleotides
that are mutated at position 1 [A(1)>T and A(1)>G] (see
Discussion). It should be noted that the changes that are
introduced into the mutant substrates could influence the
function of the oligonucleotides as targets for integration.
The A nucleotides at positions 10 and 13 were also shown
to be important for cleavage and integration by IN; the
substrates A(10)>G and A(13)>C were cleaved and inte-
grated with a lower efficiency than the wild-type substrate.
Other point mutations did not reduce the degree of site-
specific cleavage and integration. When all of the nucleotides
at positions 14 to 26 were changed [T+-G,A<-*C(26-14) in
Fig. 2A], no effect on cleavage and integration could be
detected. This suggests that the terminal 15 bp of the
retroviral DNA are sufficient for recognition by IN (see
below).
To investigate whether we could change the MoMLV U5
end sequence in such a way that it would become a target
for specific cutting by HIV-1 IN, we altered some of the
nucleotides in the MoMLV oligonucleotide to bases that are
present at similar positions in the HIV-1 U5 substrate and
were shown above to be important for cleavage and integra-
tion. For example, we showed that the A(13)>C mutation in
HIV-1 U5 resulted in a lower level of cutting by HIV-1 IN.
The MoMLV U5 sequence contains a C nucleotide at
position 13 (Fig. 2A). We changed this C nucleotide in the
MoMLV U5 sequence to an A nucleotide that is present at
the same position in the HIV-1 U5 oligonucleotide. The
resulting oligonucleotide, C(13)>A, was not a good sub-
strate for cleavage and integration by HIV-1 IN. The other
MoMLV mutants were also not cleaved efficiently by IN.
The results presented here indicate that the conserved
CA-3' dinucleotide is required for specific cleavage and
integration. Most other nucleotides at the viral DNA ends,
however, are not absolutely required for specific IN activity.
The substrate specificity is therefore probably determined by
several nucleotides at the viral DNA termini that all contrib-
ute to specific recognition. This explains why no single point
mutation in the HIV-1 U5 terminus completely blocked IN
activity and why changing single nucleotides of the MoMLV
U5 end into nucleotides that are present at similar positions
in the HIV-1 U5 end did not result in efficient site-specific
cleavage by HIV-1 IN.
Spacing requirements for specific cleavage. HIV-1 IN nor-
mally cleaves the 3' end of the blunt-ended retroviral DNA
at the phosphodiester bond that is located two nucleotides
away from the 3' terminus. Since we showed that the
sequence requirements for cutting and integration are not
very strong, we wanted to determine whether additional
specificity is provided by the position of the recognition site
with regard to the viral DNA termini. We tested whether IN
would tolerate additional nucleotides at the 3' end of the
HIV-1 U5 sequence for specific cleavage and integration.
We studied a series of mutant double-stranded oligonucleo-
tides that contain either no, one, two (the wild-type situa-
tion), three, four, five, or six nucleotides 3' of the conserved
CA-3' dinucleotide. The sequences of these substrates are
depicted in Fig. 3A; the results of the cleavage and integra-
tion assay are shown in Fig. 3B. It is clear that all substrates
were cleaved at the phosphodiester bond that is located at
the 3' side of the CA-3' dinucleotide. The blunt-ended
substrate that does not contain any residues 3' of the CA-3'
(substrate 1/2) cannot be specifically cleaved by IN. How-
ever, integrations of this substrate could be detected (Fig.
3B). The wild-type oligonucleotide, having two nucleotides
(GT-3') 3' of the CA-3' dinucleotide, was the best substrate
for site-specific cleavage and integration by IN. Specific
cleavage gradually decreased when more nucleotides were
added to the 3' end. The oligonucleotide having six nucleo-
tides 3' of the CA-3' sequence (substrate 13/14 in Fig. 3B)
was not a good substrate for cleavage. A specific band at the
position of 26 nucleotides can be seen, but this band is less
intense than the nonspecific bands at the positions of 31, 30,
29, and 24 nucleotides. The substrate containing only one
nucleotide (a G) 3' of the CA-3' was cleaved less efficiently
than the wild-type substrate. Integration events, as seen in
Fig. 3B from the products on the gel that are larger than 28
nucleotides, were most frequent when the wild-type sub-
strate was used. The other oligonucleotides that have less
than six nucleotides 3' of the CA-3' were integrated at
approximately equally low frequencies. Integrations of the
largest substrate (substrate 13/14) were not detected.
The inhibitory effect of additional base pairs at the viral
ends may result from steric hindrance of the added se-
quences in the recognition by IN. To investigate this further,
we also tested substrates in which only one DNA strand was
extended. We first investigated whether HIV-1 IN would
cleave duplex oligonucleotides in which the sequence 3' of
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the conserved CA-3' dinucleotide was present as single-
stranded DNA. The substrate containing a 3' overhang of
two nucleotides (substrate 5/2) was cleaved more efficiently
than its flush-ended counterpart, the wild-type oligonucleo-
tide (substrate 5/6) (Fig. 3C). However, integration was
slightly reduced. The other substrates tested all showed
similar patterns of cleavage; when the sequence at the 3' side
of the CA-3' dinucleotide was present as single-stranded
DNA, cleavage was greater than with the substrates that
contain double-stranded extensions. Even the substrate that
contains six bases 3' of the CA-3' sequence (substrate 13/2)
was cleaved and integrated. We tested whether the enhanced
cleavage of substrates that contain 3' protrusions was the
result of specific IN activity and not of nonspecific, 3'
single-stranded exonuclease activity caused by contaminat-
ing proteins in the IN preparation. For this purpose, the
labeled single-stranded oligonucleotide of 30 nucleotides that
contains four bases at the 3' side of the CA-3' dinucleotide
(oligonucleotide 9) was annealed with the oligonucleotide
that has the wild-type sequence (oligonucleotide 6). IN-
specific cleavage of this substrate would result in a product
of 26 nucleotides, whereas nonspecific 3' single-stranded
exonuclease activity would result in a product of 28 nucleo-
tides. In Fig. 3C, a major band of 26 nucleotides can be
observed after incubation of substrate 9/6 with IN. This
finding demonstrates that the enhanced cleavage is indeed
the result of IN activity.
We also tested whether 5' single-stranded extensions in
the DNA strand that is not cleaved by IN would influence
specific cleavage. The labeled wild-type strand of 28 nu-
cleotides (oligonucleotide 5) was annealed with oligonu-
cleotides that are longer by one (oligonucleotide 8), two
(oligonucleotide 10), three (oligonucleotide 12), or four (oli-
gonucleotide 14) nucleotides, and the resulting substrates
were incubated with IN (Fig. 3D). The level of site-specific
cleavage and integration (which could be observed after
longer exposure of the gel; data not shown) was comparable
to the wild-type level in all cases. Consequently, IN does not
seem to be hindered by these 5' single-stranded extensions.
The cleavage and integration assays with the oligonucle-
otides shown in Fig. 3A were also performed with purified
HIV-2 IN. The purification of HIV-2 IN will be described
elsewhere (34a). HIV-2 IN was indeed able to specifically
cleave the HIV-1 U5-derived substrates and showed a cleav-
age pattern similar to that of HIV-1 IN (Fig. 3E). Also, in
this case the wild-type substrate was cleaved more efficiently
than the other oligonucleotides, and cleavage decreased
gradually when more nucleotides were added to the 3' side of
the conserved CA-3' dinucleotide. Enhanced cleavage was
seen when the bases 3' of the CA-3' were present as
single-stranded DNA, as was observed for the HIV-1 IN
protein.
Specific cleavage and integration of 15-bp oligonucleotides.
We showed that the terminal 15 bp of the LTRs of HIV-1 are
sufficient for specific cleavage and integration by IN. These
terminal 15 bp, however, were present on an oligonucleotide
of 28 bp (Fig. 2). Therefore, we wanted to determine whether
an oligonucleotide of only the terminal 15 bp of the HIV-1
U5 sequence would be sufficient for specific cleavage and
integration by HIV-1 IN. Cleavage of the 15-bp substrate
was compared with cleavage of the 28-bp wild-type substrate
(oligonucleotide 5/6) and of the 28-bp substrate that contains
mutations at positions 26 to 14 (Fig. 2). We also tested
duplex oligonucleotides that have 15 nucleotides in one
strand and 28 in the other strand. The structures of the
oligonucleotides are depicted in Fig. 4A; the results are
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FIG. 3. Cleavage and integration of mutant HIV-1 U5 oligonucleotides that contain deletions or extensions at the 3' side of the conserved
CA-3' dinucleotide. (A) Structures of the oligonucleotide substrates. In each case, the top line represents the HIV-1 U5 sequence as depicted
in Fig. 2A, and the bottom line represents the complementary strand. The lines correspond to a length of 24 nucleotides. Each dot indicates
the radiolabeled phosphate group at the 5' end of the viral strand. Each IN cleavage site is depicted by an arrow. (B) Specific cleavage and
integration of the substrates shown in panel A. The substrates were incubated in the absence (left lane) or presence (right lane) of HIV-1 IN.
The autoradiograph shown in lane 1 (substrate 1/2) was exposed twice as long as those in the other lanes. Substrate numbers (from panel A)
are indicated above the lanes. Lengths of the oligonucleotide strands are shown on the right. (C) Specific cleavage and integration of
substrates that contain single-stranded extensions in the oligonucleotide strand that is cleaved by IN. Substrate numbers (from panel A) are
indicated above the lanes. (D) Specific cleavage and integration of substrates that have single-stranded extensions in the strand that is not
radiolabeled. Substrate numbers are indicated above the lanes. (E) Specific cleavage and integration of different substrates by HIV-2 IN.
Substrate numbers are indicated above the lanes.
shown in Fig. 4B. The 15-bp substrate could indeed be
cleaved by IN, but there were about equal amounts of
cleavage product of 14 nucleotides (a nonspecific product)
and of 13 nucleotides (the specific product). Integration
products could also be observed when the 15-bp substrate
was used. We conclude that the 15-bp oligonucleotide is a
substrate for specific cleavage and integration but not as
good a substrate as the 28-bp oligonucleotide. Specific
cleavage was more efficient with the substrate in which the
strand that is cleaved by IN had a length of 15 nucleotides
and the complementary strand had a length of 28 nucleotides
(substrate 18/6; Fig. 4B). In addition, integration events were
more frequent with this substrate than with the 15-bp sub-
strate. It might be suggested that more nucleotides than the
terminal 15 bp of the HIV-1 U5 sequence are required for
recognition by IN. We have shown above, however, that all
residues located more than 15 nucleotides away from the
viral termini could be altered without a detectable effect on
specific cutting. In combination with the observation that a
single-stranded extension beyond position 15 from the ter-
minus is sufficient to rescue high-efficiency cleavage, we
suggest that IN is helped by the presence of any (nonspe-
cific) extension to hold on to its viral recognition site.
Target specificity for integration. The largest products of
integration of the 15-bp oligonucleotide were 24 nucleotides
in length (Fig. 4B and data not shown). This finding demon-
strates that integration can take place at phosphodiester
bonds that are located 4 nucleotides or more removed from
the 5' end of the target DNA (13 nucleotides are obtained
from the 3' recessed strand that integrates, and apparently
the maximum length of the target DNA strand is 11 nucleo-
tides). The largest product that resulted from integration of
the wild-type substrate had a length of 50 nucleotides (as
observed after longer electrophoresis of reaction products
and overexposure of the gel; data not shown), which implies
that the 26 nucleotides of the recessed donor oligonucleotide
integrated 4 nucleotides or more removed from the 5' termini
of a 28-bp target DNA. When substrate 18/6 was used, the
largest integration products that could be detected were 38
nucleotides in length (Fig. 4B), which means that in this case
the integration site was 3 nucleotides or more removed from
the termini of the target DNA. These experiments show that
the integration site must be located at an internal position in
the target DNA and at least three nucleotides away from the
5' end of the target DNA.
An interesting observation can be made when the maximal
length of the integration product of substrate 5/17 is consid-
ered. The radiolabeled strand of the donor DNA that can
integrate is 26 nucleotides long (after site-specific removal of
two bases from the initial 28-nucleotide strand by IN); the
complementary strand is 15 nucleotides long. If the target
phosphodiester bond could be any bond in either oligonucle-
otide strand that is located 3 or more nucleotides away from
a 5' end (see above), then the maximum length of the
integration products is expected to be 51 nucleotides (26 plus
25). As shown in Fig. 4B, the ladder of integration products
extends to a position corresponding to 40 nucleotides. This
shows that the target site for efficient integration cannot be
found in the 5' single-stranded region of the 28-nucleotide
strand of substrate 5/17. Apparently, integration preferen-
tially takes place into double-stranded DNA. Close inspec-
tion of Fig. 4B reveals faint bands that correspond to
reaction products longer than 40 nucleotides. We can ex-
clude that these bands represent the products of rare double
integration events, since this explanation is not consistent
with the observation that products larger than 40 nucleotides
were not generated when substrate 18/6 was used. An
explanation might be that integration can take place with a
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FIG. 4. Specific cutting and integration of 15-bp oligonucleotides
and of oligonucleotides that contain stretches of single-stranded
DNA of different lengths. (A) Structures of the substrates. Substrate
5/6 is the same as in Fig. 3. Oligonucleotide strands 15, 16, and 17
represent the terminal 23, 19, and 15 nucleotides of the HIV-1 U5
strand that is not cleaved by IN. Each IN cleavage site is indicated
by an arrow. (B) Specific cleavage and integration of 15- and 28-bp
substrates and of substrates that contain both a 15- and a 28-
nucleotide strand. The substrates were incubated in the absence (left
lane) or presence (right lane) of HIV-1 IN. Substrate numbers (from
panel A) are indicated above the lanes. The structure of substrate
T<->G,A-QC(26-14) is shown in Fig. 2A. Lengths of the oligonucle-
otide strands are shown on the right. (C) Specific cutting and
integration of substrates having different stretches of single-stranded
DNA. Substrate numbers are indicated above the lanes.
low frequency into single-stranded DNA. However, we
cannot rule out that some base pairing of the single-stranded
DNA occurs under the reaction conditions that were used.
The conclusion that IN preferentially uses double-
stranded DNA as a target for insertion was further tested.
Oligonucleotides containing different lengths of single-
stranded DNA were studied. The structures of these sub-
strates are shown in Fig. 4A. In all cases, the strand to be
cleaved by IN is the 28-nucleotide HIV-1 U5 wild-type
strand. In the various substrates, this strand is annealed to
complementary strands that have a length of 15, 19, 23, or 28
nucleotides (the complementary wild-type strand). The com-
plementary oligonucleotides that are smaller than 28 nucle-
otides are recessed at their 3' ends relative to the 28-
nucleotide strand. The results of the cleavage and integration
assay with these substrates are shown in Fig. 4C. The
maximal length of the integration products increases as
expected with the length of the double-stranded region of the
oligonucleotides. Therefore, we conclude that integration
preferentially takes place into double-stranded rather than
single-stranded DNA.
DISCUSSION
The IN protein of HIV-1 was expressed in E. coli and
purified to near homogeneity. The sequence and spacing
requirements for efficient specific cleavage and integration of
HIV DNA by IN were studied in a direct physical assay.
HIV-1 IN was shown to be capable of specifically cutting
and integrating 28-bp oligonucleotides that mimic the U3 and
U5 termini of HIV-1 as well as HIV-2 DNA. Despite the
differences in sequence between the U3 and U5 end of
HIV-1 or HIV-2, these substrates were cleaved and inte-
grated with about equal efficiencies.
Oligonucleotide substrates that contain mutations relative
to the oligonucleotide that represents the terminal 28 bp of
the HIV-1 U5 sequence were tested. The results presented
here demonstrate that there is only a limited sequence
requirement for site-specific cleavage and integration by
HIV-1 IN. Only point mutations in the direct vicinity and at
the 5' side of the IN cleavage site could drastically reduce
cleavage and integration. Mutation of the conserved CA-3'
dinucleotide to the sequence TG-3' totally blocked cleavage
and, as a consequence integration. When the A at position 1
(Fig. 2A) was changed to a T, low-efficiency cleavage was
detected. However, integration events could not be detected
when this substrate was used. This result could be explained
by the fact that the A at position 1 of the HIV 3' ends is the
nucleotide that is coupled to the target DNA. The impor-
tance of this A nucleotide for integration has also been
observed for MoMLV (3). In this case, the integration of
plasmids, linearized by digestion with EcoRI, was studied in
a genetic assay. It was shown that integration was favored
when the termini of the plasmids were modified in such a
way that an A nucleotide was present at the 3' ends.
A limited sequence requirement for integration has been
described previously for the MoMLV IN protein, which was
provided either as cytoplasmic extract from MoMLV-in-
fected cells (37) or as a partially purified protein (3). MoMLV
IN was shown to be capable of integrating HIV DNA,
despite the considerable difference in sequence between the
termini of MoMLV and HIV DNA (3, 37); 7 of 15 nucleo-
tides at the U3 end and 9 of 15 residues at the U5 end are
different between HIV-1 and MoMLV. The integration of
HIV substrates by MoMLV IN was less efficient than the
integration of MoMLV substrates (3, 37). We show here that
despite the limited sequence requirements for integration,
HIV-1 IN is not able to specifically cleave MoMLV DNA.
Even when nucleotides 1 to 4 or 8 to 12 of the MoMLV
U5 sequence in Fig. 2A were changed to the residues that
B T-G
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are present at corresponding positions in the HIV-1 U5
sequence [substrates TT(4-3)>AG and GGGGG(12-8)
>AAATC, respectively], no efficient specific cleavage could
be seen. It should be emphasized, however, that the crite-
rion for specific cutting is rather stringent; low levels of
cleavage cannot be detected in the assay that we used.
The limited sequence requirement for specific cleavage
and integration of retroviral DNA termini raises the question
of how IN can specifically recognize its viral target site.
Besides the sequence context of the viral ends, the spacing
between the IN cleavage site and the DNA terminus is
important for cleavage and integration (see below). In vivo,
in the cytoplasm of the infected cell, the viral DNA is part of
a nucleoprotein complex that contains the IN protein as the
only detectable protein component (12). It is possible that
the IN proteins are helped, by their interaction with each
other, to recognize the retroviral DNA ends. Thus, the
interaction between the IN proteins or the continued pres-
ence of IN molecules in the right position in the viral core
particle might circumvent the need for high-specificity rec-
ognition of the viral ends by IN.
The distance between the IN cleavage site (the phospho-
diester bond 3' of the CA-3' sequence) and the retroviral
DNA terminus is important for specific cleavage by IN.
Efficient specific cleavage occurred when the IN cleavage
site is spaced two nucleotides away from the DNA end. In
the wild-type situation, the HIV-1 IN cleavage site is prob-
ably also located two nucleotides away from the DNA
terminus. This was inferred from the sequences of junction
fragments (so-called circle junctions) that are generated in
vivo after circularization of linear double-stranded viral
DNA molecules (17, 22, 23, 33, 39). We found that when
only one nucleotide was present at the 3' side of the CA-3'
sequence, the level of cleavage was less than with the
wild-type substrate. The addition of more than two nucleo-
tides to the 3' side of the CA-3' sequence resulted in a
gradual decrease of site-specific cleavage. The finding that
all oligonucleotides with more (or less) than two residues 3'
of the conserved CA-3' were indeed cleaved at the phos-
phodiester bond 3' adjacent to the CA-3' implies that the
cleavage site is determined by sequences internal to the LTR
termini. This view is consistent with the observation that
correct 3' recessed termini are formed in vivo and in vitro by
MoMLV mutants that contain additional nucleotides 3' of
the CA-3' dinucleotide (8, 26). It was demonstrated, how-
ever, that cleavage at the IN cleavage site did not occur in
vivo when this site was located 12 bases internal to the
terminus of the MoMLV DNA (26). This result is in agree-
ment with our finding that HIV-1 IN is not able to specifi-
cally cleave retroviral DNA substrates when the IN cleavage
site is located more than five nucleotides internal to the DNA
ends. Our results are further consistent with the observation
that ASLV circle junction sequences, in which the ASLV IN
recognition sites are present at internal positions, are not
efficient substrates for cleavage and, as a consequence, for
integration (18, 19). Our observations could provide an
explanation for why integrated proviruses are not substrates
for IN and therefore cannot be excised from the host DNA.
Site-specific cleavage by IN was enhanced when the
residues 3' adjacent to the conserved CA-3' dinucleotide
were present as single-stranded DNA. A stretch of single-
stranded DNA might be more accessible for specific cleav-
age by IN than is double-stranded DNA, because a single-
stranded extension may provide less steric hindrance than
does a double-stranded extension. Single-stranded exten-
sions at the 5' end near the IN cleavage site did not have any
effect on cutting and integration.
The terminal 15 bp of HIV-1 DNA are sufficient for
specific cleavage and integration by IN. Although a 28-bp
oligonucleotide that mimics the ends of HIV-1 DNA was a
better substrate for cutting and integration than was a 15-bp
substrate, it was demonstrated that this difference was not
the result of additional specific recognition of sequences in
the region that is located more than 15 bp away from the
terminus. The additional stretch of single- or double-
stranded DNA that was present in the substrates that are
longer than 15 nucleotides possibly plays in role in helping
the IN protein to hold on to its viral DNA substrate. Similar
observations have been made for many restriction endonu-
cleases that require that their recognition site be a few base
pairs removed from the ends of DNA.
It should be emphasized that the assay in which cleavage
and integration were tested represents an artificial system.
For example, the requirement for Mn2+ rather than Mg2+ as
the divalent cation for efficient specific cleavage and integra-
tion (8, 30) is not consistent with the observations that in
vitro integration of endogenous viral DNA, which is present
in nucleoprotein complexes, takes place efficiently with
Mg2+ as the divalent cation (1, 10, 15). The results concern-
ing the substrate specificity of purified IN are, however, in
agreement with what was observed in in vivo systems. The
limited requirement for specific sequences at the retroviral
DNA termini that we demonstrated for purified HIV-1 IN
has previously been shown in vivo for MoMLV IN (26). The
inability of HIV-1 IN to efficiently cleave its viral target site
when this target site is located at an internal position has also
been demonstrated in the in vivo MoMLV system (26).
Therefore, it is probable that the results that we obtained do
indeed reflect true properties of the IN protein. Further
analysis of the properties of the IN protein might therefore
contribute considerably to the knowledge of retroviral inte-
gration.
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